LOOKING FOR ASSISTANCE WITH ANALYZING AND INTERPRETING YOUR DATA?
AltraBio is a contract research company specializing in the analysis of biological and medical data using statistical methods and artificial intelligence.
Trusted globally, AltraBio serves as a research and development partner for leading companies and university hospitals across pharmaceuticals, medical devices, diagnostics, and dermato-cosmetics sectors.
How can we work together?
Partnership
Development of computational tools for data analysis in regional / national / international consortia.
Examples of current and completed projects:
Subcontracting
Data analysis for companies and university hospitals.
-
Hundreds of completed projects
-
Regular customers including top 10 pharmas and leaders in cosmetics
Funding
NEWS
November 2023
AFC Annual Congress
AltraBio is delighted to announce its presence at the next Annual [...]
October 2023
Innovative Therapies Days
AltraBio is excited to announce its presence at the upcoming Innovative [...]
July 2023
The multi-level regulation of clownfish metamorphosis by thyroid hormones.
Congratulations to the teams of Vincent Laudet from Okinawa Institute of Science [...]
May 2023
AltraBio and Tercen announce their Partnership for automated gating in clinical studies.
AltraBio SAS, a leading company in data analysis and [...]
LATEST PUBLICATIONS
2014
Idbaih, Ahmed; Mokhtari, Karima; Emile, Jean-François; Galanaud, Damien; Belaid, Hayat; de Bernard, Simon; Benameur, Neila; Barlog, Vlad-Ciprian; Psimaras, Dimitri; Donadieu, Jean; Carpentier, Catherine; Martin-Duverneuil, Nadine; Haroche, Julien; Feuvret, Loic; Zahr, Noel; Delattre, Jean-Yves; Hoang-Xuan, Khê
Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib Journal Article
In: Neurology, vol. 83, no. 16, pp. 1478–1480, 2014, ISSN: 1526-632X.
@article{pmid25209580,
title = {Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib},
author = {Ahmed Idbaih and Karima Mokhtari and Jean-François Emile and Damien Galanaud and Hayat Belaid and Simon de Bernard and Neila Benameur and Vlad-Ciprian Barlog and Dimitri Psimaras and Jean Donadieu and Catherine Carpentier and Nadine Martin-Duverneuil and Julien Haroche and Loic Feuvret and Noel Zahr and Jean-Yves Delattre and Khê Hoang-Xuan},
doi = {10.1212/WNL.0000000000000880},
issn = {1526-632X},
year = {2014},
date = {2014-10-01},
urldate = {2014-10-01},
journal = {Neurology},
volume = {83},
number = {16},
pages = {1478--1480},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Idbaih, Ahmed; Mokhtari, Karima; cois Emile, Jean-Franc; Galanaud, Damien; Belaid, Hayat; Bernard, Simon; Benameur, Neila; Barlog, Vlad-Ciprian; Psimaras, Dimitri; Donadieu, Jean; Carpentier, Catherine; Martin-Duverneuil, Nadine; Haroche, Julien; Feuvret, Loic; Zahr, Noel; Delattre, Jean-Yves; Hoang-Xuan, Kh^e
Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib Journal Article
In: Neurology, vol. 83, no. 16, pp. 1478–1480, 2014.
@article{Idbaih2014-pa,
title = {Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib},
author = {Ahmed Idbaih and Karima Mokhtari and Jean-Franc cois Emile and Damien Galanaud and Hayat Belaid and Simon Bernard and Neila Benameur and Vlad-Ciprian Barlog and Dimitri Psimaras and Jean Donadieu and Catherine Carpentier and Nadine Martin-Duverneuil and Julien Haroche and Loic Feuvret and Noel Zahr and Jean-Yves Delattre and Kh^e Hoang-Xuan},
doi = {10.1212/WNL.0000000000000880},
year = {2014},
date = {2014-10-01},
urldate = {2014-10-01},
journal = {Neurology},
volume = {83},
number = {16},
pages = {1478--1480},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Daussy, Cécile; Faure, Fabrice; Mayol, Katia; Viel, Sébastien; Gasteiger, Georg; Charrier, Emily; Bienvenu, Jacques; Henry, Thomas; Debien, Emilie; Hasan, Uzma A; Marvel, Jacqueline; Yoh, Keigyou; Takahashi, Satoru; Prinz, Immo; de Bernard, Simon; Buffat, Laurent; Walzer, Thierry
T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow Journal Article
In: J Exp Med, vol. 211, no. 3, pp. 563–577, 2014, ISSN: 1540-9538.
@article{pmid24516120,
title = {T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow},
author = {Cécile Daussy and Fabrice Faure and Katia Mayol and Sébastien Viel and Georg Gasteiger and Emily Charrier and Jacques Bienvenu and Thomas Henry and Emilie Debien and Uzma A Hasan and Jacqueline Marvel and Keigyou Yoh and Satoru Takahashi and Immo Prinz and Simon de Bernard and Laurent Buffat and Thierry Walzer},
doi = {10.1084/jem.20131560},
issn = {1540-9538},
year = {2014},
date = {2014-03-01},
urldate = {2014-03-01},
journal = {J Exp Med},
volume = {211},
number = {3},
pages = {563--577},
abstract = {Trail(+)DX5(-)Eomes(-) natural killer (NK) cells arise in the mouse fetal liver and persist in the adult liver. Their relationships with Trail(-)DX5(+) NK cells remain controversial. We generated a novel Eomes-GFP reporter murine model to address this question. We found that Eomes(-) NK cells are not precursors of classical Eomes(+) NK cells but rather constitute a distinct lineage of innate lymphoid cells. Eomes(-) NK cells are strictly dependent on both T-bet and IL-15, similarly to NKT cells. We observed that, in the liver, expression of T-bet in progenitors represses Eomes expression and the development of Eomes(+) NK cells. Reciprocally, the bone marrow (BM) microenvironment restricts T-bet expression in developing NK cells. Ectopic expression of T-bet forces the development of Eomes(-) NK cells, demonstrating that repression of T-bet is essential for the development of Eomes(+) NK cells. Gene profile analyses show that Eomes(-) NK cells share part of their transcriptional program with NKT cells, including genes involved in liver homing and NK cell receptors. Moreover, Eomes(-) NK cells produce a broad range of cytokines, including IL-2 and TNF in vitro and in vivo, during immune responses against vaccinia virus. Thus, mutually exclusive expression of T-bet and Eomes drives the development of different NK cell lineages with complementary functions.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}